GlassScriptPhysician profile
Raymond Parker
NPI 1639165533
$14,031.08
in general payments reported to CMS, 2019-2025
32 companies · $2,505 in 2025
The $2,505 reported for 2025 was more than what 80% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,419 · 2020: $1,137 · 2021: $1,099 · 2022: $1,741 · 2023: $3,058 · 2024: $2,072 · 2025: $2,505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,618 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,618.07 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,804.66 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $3,292.25 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,422.22 | 2019-2025 | Ofev, Jascayd, Stiolto Respimat |
| Insmed, INC. | $561.61 | 2019-2025 | Arikayce, Brinsupri |
| Mallinckrodt Hospital Products INC. | $511.81 | 2020-2025 | Acthar |
| Sunovion Pharmaceuticals INC. | $463.65 | 2019-2020 | |
| Genzyme Corporation | $434.94 | 2021-2025 | |
| Genentech USA, INC. | $405.73 | 2019-2022 | |
| Verona Pharma, INC. | $257.39 | 2025 | Ohtuvayre |
| Amgen INC. | $235.14 | 2022-2025 | Tezspire |
| Advanced Respiratory, INC | $223.72 | 2019-2021 | |
| Baxter Healthcare | $209.36 | 2022-2025 | Hillrom - Life 2000 Ventilation System, Hillrom - Volara System, Hillrom - Vest System Model 105 Home Care |
| Mallinckrodt Enterprises LLC | $151.81 | 2019 | |
| Ani Pharmaceuticals, INC. | $147.52 | 2022-2024 | Purified Cortrophin Gel |
| Mylan Specialty L.P. | $138.25 | 2019-2024 | Yupelri |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $120.39 | 2019-2025 | Vest Therapy Und, (9369) Reusable Vest |
| Regeneron Healthcare Solutions, INC. | $113.41 | 2022-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $91.99 | 2019-2025 | Uptravi, Opsumit |
| Inspire Medical Systems, INC. | $56.08 | 2023 | Inspire |
| Circassia INC. | $53.55 | 2019 | |
| Paratek Pharmaceuticals, INC. | $46.28 | 2023 | Nuzyra |
| E.R. Squibb & Sons, L.L.C. | $43.74 | 2021 | |
| Pfizer INC. | $41.79 | 2021-2023 | |
| Grifols USA, LLC | $36.23 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.15 | 2022 | |
| Viatris Specialty LLC | $25.00 | 2025 | Yupelri |
| Gilead Sciences, INC. | $22.15 | 2021 | |
| Lilly USA, LLC | $20.80 | 2025 | Zepbound |
| Merck Sharp & Dohme LLC | $19.01 | 2023 | |
| Electromed, INC. | $18.66 | 2025 | Smartvest |
| Bayer Healthcare Pharmaceuticals INC. | $16.50 | 2019 | |
| Hikma Pharmaceuticals USA | $15.29 | 2023 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Parker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.